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Background/aim: Acetaminophen (APAP) overdose results in severe liver damage that may develop into acute liver failure. Recent
studies have demonstrated that inhibition of poly(ADP-ribose) polymerase (PARP) decreases tissue necrosis and inflammation. We
evaluated the efficacy of 3-aminobenzamide (3-AB), a PARP inhibitor, in a rodent model of APAP-induced hepatotoxicity.
Materials and methods: Twenty-four Sprague-Dawley rats were divided equally into 3 experimental groups: sham group, APAP group,
and APAP + 3-AB group. In the experimental treatment groups APAP was administered orally at 1 g/kg and, in the APAP + 3-AB group,
3-AB was administered intraperitoneally at a dose of 20 mg/kg exactly 1 h after APAP treatment. Surviving animals were euthanized
48 h after initial APAP administration. Blood samples and liver tissues were collected for histopathological and biochemical analysis.
Results: A panel of oxidative stress parameters, as well as serum aspartate aminotransferase, alanine aminotransferase, neopterin, and
nitrite/nitrate and histological injury scores, were significantly reduced among the APAP + 3-AB treatment group relative to the group
treated with APAP alone (P < 0.05, APAP vs. APAP + 3-AB).
Conclusion: The present study demonstrates that 3-AB inhibited APAP-induced hepatic injury and reduced neopterin levels. Results of
the present study indicate that PARP inhibitors may be an effective adjuvant therapy resulting in improved outcomes in APAP-induced
hepatotoxicity.
Key words: Acetaminophen, toxicity, PARP inhibition, neopterin, nitrosative stress, oxidative stress

1. Introduction
Acetaminophen (N-acetyl-para-aminophenol, APAP)
is a commonly used analgesic medication with potent
antiinflammatory effects. Although it is considered safe
at therapeutic doses, excessive doses of APAP may result
in severe centrilobular liver injury with potentially fatal
results, including fulminant hepatic failure (1,2).
APAP overdose is clinically significant as APAP is
the most common cause of drug-induced liver failure
in the United States and Great Britain (3). In addition,
animal models of APAP overdose have been used
extensively to evaluate novel hepatoprotective agents.
The mechanism of APAP-induced hepatic damage has
been well characterized in both animals and humans
(4–6). Initial morphological changes to the liver following
* Correspondence: mdonmezm@gmail.com
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APAP overdose include glycogen loss and vacuolization of
centrilobular hepatocytes, hepatocyte nuclear distortion,
and single-cell necrosis with pyknotic nuclei exhibiting
eosinophilic degeneration. In more advanced stages, the
centrilobular zones of the liver exposed to severe toxic
injury exhibit massive necrosis including confluent zones
of anuclear, eosinophilic hepatocytes. This damage has
been predominantly attributed to the active metabolite
of APAP, N-acetyl-para-benzoquinoneimine (NAPQI),
which depletes cytoplasmic glutathione (GSH) stores and
forms nonspecific covalent bonds with macromolecules
that lead to dysfunction and eventual cell death (5).
In addition, APAP enhances generation of reactive
oxygen intermediates that contribute significantly to
hepatotoxicity (7,8).
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At therapeutic dosages APAP is excreted efficiently
in nontoxic glucuronic acid and sulfate conjugates (9).
Only a small percentage of APAP is converted to NAPQI
by cytochrome P-450–mediated oxidases when used at
recommended dosages. In the reduced form, intracellular
GSH is conjugated to NAPQI, the detoxifying main
byproduct of APAP metabolism (10,11). APAP toxicity
at high dosages involves metabolic activation and the
formation of a reactive metabolite, presumably NAPQI
(12). However, exhaustion of intracellular GSH enables
covalent conjugation of NAPQI with cellular proteins
(4,13), including mitochondrial macromolecules
(14,15). Mitochondrial dysfunction occurs as a result
of the inhibition of mitochondrial respiration by
NAPQI conjugates (16,17), increasing mitochondrial
oxidant stress and peroxynitrite formation (18–20). As
a result, the amount of available ATP decreases (16,19)
and mitochondrial cytochrome c is released (21,22).
Mitochondrial permeability and the collapse of the
mitochondrial membrane result in necrotic cell death
(4,23).
DNA fragmentation and mitochondrial dysfunction
are early events in the pathogenesis of APAP toxicity
(24,25). Shen et al. demonstrated that DNA fragmentation
is a significant process in the cell injury and that the
application of a general endonuclease inhibitor prevents
DNA fragmentation and protects against APAP-induced
liver injury (26). The precise role of endonucleases
has not yet been identified; however, current evidence
suggests that endonucleases may play a more important
role than caspase-activated desoxyribonuclease (CAD)
in disease pathogenesis. APAP overdose has not been
associated with CAD activation (21,27,28), and the DNA
fragments generated during APAP-induced toxicity
differ substantially from those generated during caspasedependent apoptosis (29).
Poly(ADP-ribose) polymerase (PARP) catalyzes the
modification of nuclear proteins by poly-ADP ribosylation.
PARP is central to the cellular response to DNA damage
and is activated by severe DNA injury. Extensive PARP
activation exhausts the intracellular nicotinamide adenine
dinucleotide (NAD) pool, an essential metabolic cofactor
required in the mitochondrial electron transport chain
(30). DNA repair processes are inhibited in the absence
of sufficient energetic resources, resulting in cellular
dysfunction and necrotic cell death. PARP plays a
significant role as a mediator of cell death and subsequent
tissue injury and cellular dysfunction. Oxidative/nitrosative
stress is also a significant factor in the pathogenesis of
liver toxicity (31). PARP contributes to the escalation
of inflammatory processes and the pharmacological
inhibition of PARP functions has been demonstrated
to suppress the expression of inflammatory mediators
including cytokines, chemokines, and cellular adhesion

molecules (32). To date, numerous pharmacologic agents
and various molecular mechanisms have been examined
in the attempt to develop new therapeutic approaches to
overdose-related APAP toxicity. Among these mechanisms
of action is PARP activation. APAP overdose induces DNA
fragmentation and the subsequent excessive activation of
PARP (33). Interestingly, PARP antagonists have been
demonstrated to protect against APAP hepatotoxicity in
mice (34). PARP inhibitors have also been evaluated as
potent antiinflammatory agents (35,36).
Pharmacologic inhibition of PARP has proven to be
an effective treatment for a variety of disease processes,
including cancer. Certain cancer cell lineages are highly
dependent on PARP, much more so than comparable
healthy cells, making PARP an attractive target for cancer
therapy. PARP inhibitors have also been considered as a
potential treatment for acute life-threatening diseases,
including stroke and myocardial infarction, as well as
long-term neurodegenerative disease (37).
3-Aminobenzamide (3-AB) is a well-known inhibitor
of PARP (38). PARP activation depletes intracellular
stores of NAD (39). 3-AB is a close NAD+ analog capable
of binding PARP at the active site and inhibiting NAD+
depletion. 3-AB may have potential as an anticancer drug
(39).
Delayed medical treatment for APAP overdose is
associated with increased mortality and significant clinical
complications. In an attempt to address the deficits in
current medical therapy for APAP overdose, we evaluated
the efficacy of the PARP inhibitor 3-AB on hepatotoxic
injury and mortality due to APAP overdose in rats.
2. Materials and methods
2.1. Animals and study groups
The Institutional Committee on the Care and Use of
Animals reviewed and approved all animal procedures
conducted in this study (Issue 09/67, 09.11.2009). Twentyfour male Sprague-Dawley rats (200–250 g) bred in the
animal laboratory of our institution were randomly divided
into 3 equal groups: sham group (N = 8), APAP group (N
= 8), and APAP treatment with 3-AB therapy group (N
= 8). Prior to the experiment the animals were fed with
standard rat chow diet and given water ad libitum, and the
animals were housed in cages with controlled temperature
and a 12-h light/dark cycle for at least 1 week.
2.2. Induction of hepatotoxicity
A suspension of APAP (Pharmaceutical Factory of Turkish
Armed Forces, Ankara, Turkey) was prepared in warm
distilled water and administered to experimental rats at
a dose of 1 g/kg by oral gavage as previously described
(40). Following APAP administration, the animals were
returned to their cages to recover. Water and food were
available ad libitum.
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2.3. Treatment procedure
In the treatment procedure, 20 mg/kg 3-AB was
administered intraperitoneally once daily for 2 days
starting 1 h after the induction of toxicity with APAP in
the rats in the APAP + 3-AB experimental group.
2.4. Sample collection
All the surviving animals were anesthetized for laparotomy
at 48 h after hepatotoxic induction. Blood samples were
obtained for biochemical analyses by cardiac punctuation,
and serum was obtained by centrifugation of the whole
blood samples. The liver tissues were harvested for
histological and biochemical analysis. A section of liver
tissue from each animal was fixed in 10% formalin for
histopathological evaluation, and the remaining liver tissue
samples were stored at –80 °C for future measurement of
antioxidant enzyme activity and tissue lipid peroxidation.
All experimental animals were euthanized by decapitation.
2.5. Tissue preparation and biochemical analysis
Liver tissue samples were homogenized in ice-cold
phosphate buffered saline (pH 7.4) using a homogenizer
(Heidolph Diax 900; Heidolph Elektro GmbH, Kelheim,
Germany). The resulting supernatant was used for all
biochemical assays. The protein content of the tissue
homogenates was measured using the Lowry method with
bovine serum albumin as the standard protein (41).
The overall level of lipid peroxidation was measured
using the thiobarbituric acid (TBA) reaction (42).
A spectrophotometric measurement at 535 nm was
used to quantify the reaction products of TBA and
malondialdehyde (MDA). The calculated MDA levels are
expressed as nM/mg protein.
Superoxide dismutase (SOD) activity was assayed using
the nitroblue tetrazolium (NBT) method as described
previously (43). This method is based on the reduction of
NBT to blue formazan by ·O2-, which has strong absorbance
at 560 nm. One unit of SOD is defined as the amount of
protein that inhibits the rate of NBT reduction by 50%.
The estimated SOD activity is expressed as U/g protein.
Glutathione peroxidase (GSH-Px) activity was
measured using a method described previously (44).
Briefly, GSH-Px activity was coupled to the oxidation of
nicotinamide adenine dinucleotide phosphate (NADPH)
by glutathione reductase. The oxidation of NADPH was
quantified by spectrophotometric measurement at 340 nm
and 37 °C for 5 min. GSH-Px activity is calculated as the
slope of the line or as mM NADPH oxidized per minute.
GSH-Px activity is presented as U/g protein.
Serum aspartate aminotransferase (AST), alanine
aminotransferase (ALT), alkaline phosphatase (ALP),
and gamma-glutamyl transferase (GGT) concentrations
were measured by a spectrophotometric technique using
an Olympus AU-2700 autoanalyzer and commercially
available kits (Olympus, Hamburg, Germany) and are
expressed as U/L.
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Serum neopterin (NP) concentrations were
determined using high-pressure liquid chromatography
(Agilent Technologies 1200 Series System, Santa
Clara, CA, USA) with a fluorescence detector as
described previously (45). In brief, 0.1 mL of 2 mmol/L
trichloroacetic acid was added to 0.4 mL of serum or
tissue supernatant and the mixture was cooled in an ice
bath for 10 min. The precipitated protein was removed by
centrifugation at 2000 × g for 10 min. Twenty microliters
of the supernatant was filtered through a 0.2 mm filter
and injected into the chromatographic system. Separation
of NP was achieved with a 250 × 4.6 mm2 ID Allsphere
ODS-2, C18 RP column with a particle size of 5 mm
(Alltech, Deerfield, IL, USA) fitted with a 10 × 4.6 mm2
ID Allsphere ODS-2 guard column (Alltech) using 0.015
mM/L phosphate buffer (pH 6.4) as the mobile phase
(isocratic elution) at a flow rate of 0.8 mL/min. The peaks
detected by the fluorescent detector (Ex: 353 nm; Em:
438 nm) were used for quantification. Serum neopterin
concentrations are expressed as nM/L.
2.6. Serum nitrite-nitrate (NOx)
Serum samples were passed through 0.45 µm
pore membrane nitrocellulose filters prior to NOx
analysis. NOx levels were detected by means of an ion
chromatograph (Dionex ICS-1000, Sunnyvale, CA, USA).
Anion and guard columns (AS-9HC/AG-9HC, CS12A/
CG12A, Dionex) and automated suppression were used.
NOx levels were quantified using separate standard
solutions for each ion and are expressed as mg/L (46).
2.7. Histopathologic analysis
Tissue specimens were fixed in 10% formalin for 24 h,
then embedded in paraffin and cut into sections 5 µm
thick. Slides were stained with hematoxylin and eosin
(H&E) and examined under a light microscope. Each
slide was evaluated by an expert investigator blinded
to the identity of the experimental groups and liver
injury was scored according to the method previously
described by Gul et al. (47). Liver injury was scored for
the degree of edema (0–4), inflammatory infiltration
(0–6), hemorrhage (0–6), and ballooning (prenecrotic
degeneration; 0–8). The total area of edema, infiltration,
hemorrhage, and ballooning was also taken into account.
The summation of the individual histological parameters
resulted in a single score per slide with a maximum score
of 24.
2.8. Statistical analysis
Results are expressed as median (min–max). Normality
of the sampling distribution was analyzed using the
Kruskal–Wallis test. Comparison between groups was
conducted using the Mann–Whitney U test. P < 0.05
was considered statistically significant. All analyses were
performed using SPSS 11.0 (SPSS Inc., Chicago, IL, USA).
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3. Results
3.1. Animals
Over the course of the experimental treatment, 3 of 8
rats in the APAP group died (1 and 2 animals at the 24th
and 36th hours, respectively), while all animals in the
sham treatment and APAP + 3-AB experimental groups
survived until the end of the experiment (Figure 1). The
overall survival in the APAP + 3-AB treatment group
was significantly greater than that of the rats treated with
APAP alone (P = 0.025).
3.2. Serum ALT and AST activities
Serum ALT and AST levels were significantly elevated in
the APAP treatment group relative to the sham treatment
and APAP + 3-AB treatment groups (P < 0.05 APAP vs.
sham or APAP + 3-AB), indicating substantial liver tissue
damage. There was no statistically significant difference
in the ALT and AST values in the APAP + 3-AB group
compared to the sham group (Table 1).
3.3. Serum neopterin levels
The APAP group exhibited significantly increased serum
NP levels (P < 0.05, APAP vs. the other groups). The
APAP + 3-AB group had significantly decreased serum
NP levels in comparison to the APAP group, but serum
neopterin remained elevated in the APAP + 3-AB relative
to the sham group (P < 0.05, APAP + 3-AB group vs. other
groups) (Table 1).
3.4. Serum NOx levels
Serum NOx levels in the APAP group were increased
significantly relative to the other experimental groups (P
< 0.05, APAP vs. sham or APAP + 3-AB). The APAP +
3-AB treatment group had significantly decreased serum
NOx levels relative to the APAP group, but increased levels

1.0

Cum survival

0.8

0.6
Log rank = 4.994, P = 0.025

0.4

Groups
Sham
APAP
APAP+3-AB

0.2

0.0
20

25

30
35
40
Experiment hours

Figure 1. Survival rates in the groups.
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Table 1. Biochemical parameters in the groups.
Sham

APAP

APAP + 3-AB

(N = 10)

(N = 10)

ALT (U/L)

74.0 ± 18.6

1263.8 ± 264.6

AST (U/L)

148.0 ± 29.8

586.0 ± 152.6 a

236.0 ± 51.4 a, b

Neopterin
(nM/L)

4.2 ± 1.4

15.2 ± 1.8 a

7.2 ± 1.5 b

(N = 10)
a

126.0 ± 58.8 a, b

: P < 0.05, statistically different from sham group.
: P < 0.05, statistically different from APAP group.

a

b

relative to the sham treatment group (P < 0.05, APAP +
3-AB group vs. APAP and sham group) (Table 2).
3.5. Tissue lipid peroxidation levels
MDA levels in the APAP group were significantly increased
in comparison to the other treatment groups, indicating
increased hepatocellular damage (P < 0.05, APAP vs. sham
or APAP + 3-AB). However, MDA levels were significantly
decreased in the APAP + 3-AB group compared to the
APAP group (P < 0.05, APAP + 3-AB vs. APAP) (Table 2).
3.6. Tissue antioxidant enzyme activities
The total tissue SOD activity in the APAP and APAP +
3-AB groups was significantly increased relative to the
sham treatment group (P < 0.05, APAP and APAP +
3-AB vs. sham treatment). The total tissue SOD activity
was significantly greater in the APAP + 3-AB group in
comparison to the APAP treatment group (P < 0.05, APAP
+ 3-AB treatment vs. APAP treatment) (Table 2).
GSH-Px activity was significantly decreased in the
APAP treatment group in comparison to the shamoperated group (P < 0.05, APAP treatment alone vs. sham
group). GSH-Px activity was significantly greater in the
APAP + 3-AB treatment group in comparison to the APAP
group, but decreased relative to the sham-operated group
(P < 0.05, APAP + 3-AB vs. sham and APAP) (Table 2).
3.7. Histopathologic findings
Blinded histological examination did not detect any
characteristics of liver or kidney injury in the shamoperated group. Conversely, all of the animals in the APAP
treatment group exhibited severe liver injury with marked
central necrosis, hemorrhaging, leukocyte infiltration,
and all indicators of hepatotoxicity. In the APAP + 3-AB
treatment group, hepatic injury parameters, including
necrosis and leukocyte infiltration, were significantly less
prevalent than in the animals treated with APAP alone (P
< 0.05, APAP + 3-AB vs. APAP) (Table 3; Figure 2).
4. Discussion
Hepatotoxicity due to APAP overdose was first reported
by Davidson and Eastham (48). They performed a
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Table 2. Tissue peroxidation and antioxidant parameters in the groups.
Sham

APAP

APAP + 3-AB

(N = 10)

(N = 10)

(N = 10)

0.59 ± 0.13

1.86 ± 0.52 a

0.95 ± 0.12 a, b

662.28 ± 212.56

248.44 ± 82.60 a

396.58 ± 82.36 a, b

GSH-Px (U/g protein)

66.28 ± 11.24

20.24 ± 5.36 a

40.34 ± 4.84 a, b

NOx (U/L)

4.10 ± 1.53

8.92 ± 1.76 a

5.26 ± 1.28 a, b

MDA
(mM/g protein)
SOD
(U/g protein)

a

: P < 0.05, statistically different from sham group.
: P < 0.05, statistically different from APAP group.

b

Table 3. Pathologic scores. Data are expressed as median (min–max).
Groups

Sham
(N = 10)

APAP
(N = 10)

APAP + 3-AB
(N = 10)

Edema

0 (0–1)

3 (2–4) a

2 (1–2)a

Hemorrhage

0 (0–1)

3 (2–-6) a

2 (1–-4)a, b

Leukocyte infiltration

0 (0–1)

3 (2–5)

1 (1–2)a, b

Ballooning (prenecrotic change)

0 (0–0)

6 (2–7) a

Total score

0 (0–3)

15 (8–22)

a

2 (1–3)a, b
a

7 (4–11) a, b

: P < 0.05, statistically different from sham group.
: P < 0.05, statistically different from APAP group.

a

b

histological examination of a large number of liver
sections demonstrating fulminant hepatic necrosis. This
necrosis was located primarily in the centrilobular tissues.
This landmark publication described for the first time
eosinophilic degeneration of hepatocytes with pyknosis
of the nuclear material, and vacuolization and early
degenerative changes in the peripheral cells surrounding
the portal areas. The cases described exhibited mild
polymorphonuclear leukocytic infiltration with fulminant
necrosis confined primarily to the hepatocytes of the
centrilobular regions of the liver
Prescott et al. published a thorough report of the
clinical and biochemical characteristics in clinical cases
of APAP toxicity, demonstrating a distinct increase in
serum ALT and AST activities, mild hyperbilirubinemia,
and a significant increase in prothrombin clotting time
(49). Other clinical reports have suggested that a delayed
elimination half-life of APAP may contribute to increased
hepatotoxicity at high dosages (50). In some cases,
nephrotoxicity may develop in addition to hepatotoxicity
(51,52).
The overall clinical features of APAP-induced
hepatotoxicity and the pathogenesis of associated
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congestion and coagulative necrosis have been well
characterized. However, the mechanistic understanding
of this disease is less well developed. Laskin (53,54)
proposed that the interaction between parenchymal and
nonparenchymal cells is a critical event in the development
of APAP-induced centrilobular necrosis. Nonparenchymal
cells, such as Kupffer cells, are a significant source of
chemotactic factors and generate a substantial quantity
of reactive oxygen intermediates that are responsible
for the hepatic acute phase response (55,56). However,
histopathological examination is a more effective measure
of changes in vascular congestion and hepatocellular
necrosis (57).
To the best of our knowledge, the current study is among
the first to demonstrate the therapeutic benefits of 3-AB
in treating APAP-induced hepatotoxicity. In addition, this
study incorporates unique parameters in APAP-induced
toxicity, such as survival rate and serum neopterin. Our
results demonstrate that the inhibition of PARP with 3-AB
had a significant protective effect against APAP-induced
pathology and related serum markers. 3-AB treatment
was also associated with a reduction in hepatic oxidative
stress in accordance with the histopathological findings.
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A

B

C

Figure 2. A) Representative photograph from sham group showing normal hepatocytes and a central vein.
B) Photograph from APAP group, with massive edema and ballooning (prenecrotic degeneration) of pericentral
hepatocytes. C) Photograph from APAP + 3-AB group, where inhibition of PARP with 3-AB treatment normalized
edema and ballooning. H&E, scale bars = 200 µm.

Modulation of serum NP and decreased serum AST and
ALT were observed in the animals treated with 3-AB
following APAP-induced hepatotoxicity, but not in the
animals treated with APAP alone. Most importantly, 3-AB
treatment significantly increased APAP-induced hepatic
injury survival. Together, these findings demonstrate that
3-AB administration is protective against the significant
effects of APAP-induced hepatotoxicity.
The reduction in tissue MDA (an oxidative stress
marker) levels and GSH-Px activity levels, and the increase
in SOD enzymatic activity, suggest that the inhibition of
PARP by 3-AB limited necrotic damage and the depletion
of metabolic cofactors such as NAD, preventing oxidative
injury.
The administration of 3-AB ameliorated APAPinduced inflammation and injury in both hepatic and
renal tissues. We propose that PARP inhibition enables
improved maintenance of intracellular energy stores.
When hepatic cells are exposed to toxic levels of APAP,
the formation of NAPQI is known to result in DNA
fragmentation and other macromolecular distortion

within the cytoplasm. This DNA fragmentation represents
a significant mutagenic event and requires the use of
cellular energy stores to prevent subsequent cell necrosis.
This necrotic process may be prevented with a PARP
inhibitor such as 3-AB; however, in the later stages PARP
inhibition may have to be terminated to allow for the
continuation of DNA repair processes.
Elevated ALT and AST activities are well-known
indicators of liver damage. (58). Necrotic damage to
the liver causes leakage of AST and ALT through the
hepatocellular membrane and into the bloodstream.
Although elevated concentrations of liver enzymes in
the serum may indicate hepatocellular damage, AST and
ALT are poor prognostic indicators of the severity of liver
injury (59). Others have reported the elevation of serum
NP levels in the rat model of APAP-induced liver injury
in a dose-dependent manner (60). In the present study,
we demonstrate that the elevation of liver enzymes and
NP levels associated with APAP-induced hepatotoxicity
is inhibited by the PARP inhibition activities of 3-AB,
in correlation with the histopathological findings. NP
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is a critical indicator of cellular immunity produced by
monocytes/macrophages in response to the cytokine
interferon-γ. NP expression is associated with varying
stages of disease progression (61). Our observation of
decreased NP levels in the APAP + 3-AB treatment group
suggests that administration of 3-AB may impair the
recruitment of monocytes and macrophages to the liver
tissue. The histological observation of decreased leucocyte
infiltration among the APAP + 3-AB treatment group
compared to the animals receiving APAP alone supports
this hypothesis.
PARP inhibition with 3-AB was associated with
significant improvements in liver function, as evidenced
by reduction in serum GGT, ALT, and AST levels among
animals treated with APAP. Decreased severity of hepatic
injury likely resulted in reduced leakage of liver enzymes
into the serum.
Peroxynitrite formation occurs in APAP-induced
liver injury and may contribute to later pathological
hepatocellular events (19). Peroxynitrite is a strong oxidant
that is highly reactive with most biological molecules (31).
In the current study, serum NOx levels were elevated

among the animals receiving APAP alone compared
to the sham treatment group. However, therapeutic
treatment with 3-AB resulted in decreased serum and
tissue NOx relative to animals treated with APAP alone.
PARP inhibition thus had a beneficial effect in directly
or indirectly decreasing excessive NOx production in
injured hepatocytes. The prevention of inflammatory and
necrotic processes through PARP inhibition may impair
the generation of superoxide radicals that react with NO to
yield the highly hepatotoxic molecule peroxynitrite.
Protein expression will enhance the understanding
of the molecular processes involved in the alleviation of
APAP-induced hepatotoxicity by PARP inhibition. The
effects of 3-AB on mitochondrial function may be critical
in elucidating the therapeutic effects of PARP inhibition at
the molecular level. Additional benefits of 3-AB treatment
in injured liver tissue may be attributable to the modulation
of inflammatory pathways and the altered expression of
cytokines and antioxidant enzymes.
In conclusion, this study demonstrates that 3-AB
protects against APAP-induced hepatic injury in rats.
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